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Abstract 
Purpose 
The purpose was to assess the differences between subcutaneous basal/bolus and sliding scale insulin 
protocols in patients admitted with type 2 diabetes on non-critical care units. 
Methods 
A retrospective review of electronic medical records was conducted on a convenience sample of 
inpatients in a central-city teaching hospital. 
Results 
The findings were that basal/bolus protocols achieved American Diabetes Association glycemic targets 
on fasting, mean, and discharge blood glucoses. 
Conclusions 
This study provided insight into glycemic control and interdisciplinary education needs at this hospital. 
Evidence revealed that basal/bolus insulin protocols can achieve glycemic targets. 
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Hyperglycemia, or high blood glucose, among hospitalized patients is associated with adverse short- 
and long-term outcomes such as increased lengths of stay and increased time for healing. In fact, in 1 
study,1 the association of hyperglycemia and mortality was greater in patients without a history of 
diabetes compared to those with diabetes. A retrospective analysis determined that nearly 25% of 
patients admitted with diabetes were hyperglycemic, with a blood glucose > 200 mg/dl (11.1 mmol/l) 
upon admission because they were either poorly controlled on their prehospital diabetes regimen, or 
they were poorly controlled because of their primary admission diagnosis, which often was related to 
infection.2 
For the majority of nonacute hospitalized patients with diabetes, pre-meal blood glucose targets 
should generally be < 140 mg/dl (7.8 mmol/l), with random blood glucose levels < 180 mg/dl (10.0 
mmol/l). Special considerations need to be taken into account, however, for patients with severe 
comorbidities and those who are terminally ill when higher glucose targets may be warranted.3 
Subcutaneous insulin therapy is the preferred method of glycemic control on non-critical care units for 
patients with diabetes. There are various types of insulin protocols for treating hyperglycemia in the 
hospital setting. Treatment options include sliding-scale insulin or basal/bolus insulin therapy. 
Hospitalized patients are prone to large variances in blood glucoses. Because of this, effective 
treatment is required to maintain satisfactory, safe glucose control. Subcutaneous sliding-scale insulin 
has been long-used as routine therapy for treatment of hyperglycemia and involves administering pre-
meal insulin 4-6 times per day, depending on the pre-meal blood glucose. 
Although it has been frequently used, there is a lack of evidence supporting the effectiveness of this 
practice.4 Sliding-scale insulin usually consists of regular insulin or rapid-acting insulin given alone. This 
technique has been shown to be ineffective for the following reasons: the reactive approach can lead 
to rapid swings in blood glucose, resulting in hyperglycemia and hypoglycemia, the regimen in place at 
admission is likely to be used throughout the hospitalization without appropriate change or titration, 
and hyperglycemia is treated after the fact instead of proactively anticipating need. In a retrospective 
study, Freedman et al5 proposed that patients with high admission blood glucoses were more likely to 
be placed on a sliding scale insulin (SSI) protocol. Freedman also indicated that other patients were 
often placed on a sliding scale protocol because it was a method that was passed down from trainee 
to trainee as an easy, “auto-pilot” way to treat diabetes in the hospital, a method that would limit the 
need for physician intervention. The hazards of sliding-scale insulin use exceed the advantages of 
its convenience, and thus prolonged therapy using this insulin as the sole source of treatment is dis-
couraged.6 
In the noncritical care setting, scheduled subcutaneous insulin that delivers basal, nutritional (bolus), 
and correction (supplemental) doses are preferred because this type of therapy is shown to be more 
physiological—ie, more closely matching endogenous basal and bolus insulin secretion.3 However, 
SSI is still predominantly used on the study hospitals' medical non-critical care units. Insulin protocols 
at this hospital are prescribed by hospitalists, residents, surgeons, internal medicine physicians, family 
medicine physicians, and nurse practitioners (NPs)/physician assistants. The orders are implemented 
by the staff nurses and are often a source of frustration as they are usually the first caregiver to 
recognize that the blood glucose is not being well-controlled. 
Diabetes NPs can be consulted to collaborate with staff nurses on a regimen change and patient 
education needs. Diabetes NPs can implement best practices as they relate to control of inpatient 
hyperglycemia and are key providers to coordinate and provide inpatient diabetes care. 
Methods 
A retrospective chart review of patients hospitalized with known type 2 diabetes was conducted for 
the purpose of quality improvement at a 140-bed, central-city teaching hospital in Milwaukee, WI. The 
chart review was specifically performed to study the outcomes that basal bolus vs SSI protocols had on 
fasting, mean, and discharge blood glucoses, length of stay (LOS), and episodes of mild/moderate or 
severe hypoglycemia. Inclusion criteria included patients age 18-80, admitted to general medical units, 
and managed on either basal/bolus or SSI protocols. 
Exclusion criteria included patients admitted to critical care units, including intermediate care units, as 
well as surgical and obstetrical units. Patients who were found to have undergone surgery, though 
admitted initially to a medical unit, were excluded, as well as those who received steroids, oral 
diabetes agents, or intravenous insulin at any time during their stay. Patients who were hospitalized for 
fewer than 3 days were also excluded. 
The institutional review boards at the study hospital and Marquette University approved the quality 
improvement study. Clinical information services at the study hospital conducted a search using ICD 9 
diagnosis codes of 250.0 and 250.02 and the aforementioned inclusion and exclusion criteria for 
patients admitted between January 1, 2009, and January 1, 2012. Lists were provided by clinical 
information services that identified patients by their medical record number, discharge date, LOS, age, 
sex, ethnicity, admission diagnosis, and nursing unit. 
A review of the electronic record for each patient who met the inclusion criteria was conducted in the 
sequence in which they appeared. Subjects were de-identified. The blood glucose data included 
glucose levels tested before each meal and at bedtime. The goal of insulin therapy was to maintain 
fasting and pre-meal blood sugars < 140 mg/dl (7.78 mmol/l), and overall < 180 mg/dl (10.0 mmol/l) 
while avoiding hypoglycemia (no lower than 70 mg/dl or 3.89 mmol/l).3 The primary goal was to 
determine differences between the 2 groups of subjects based on the type of insulin protocol. 
Sample 
A power analysis was conducted using the G*Power calculator (Buchner, Erdfelder, and Faul, 
Duesseldorf Germany) for an independent t-test. It was concluded that to achieve significance, a 
sample of 128 patients with type 2 diabetes was required. The sample size was evenly divided between 
patients placed on basal/bolus protocols and those placed on SSI protocols. The demographic variable 
data collected for the sample included age, ethnicity, sex, admission blood glucose, admission 
diagnosis, hemoglobin A1C, serum hemoglobin, serum creatinine, and white blood cell count. These 
particular variables were chosen because they can have an impact on the blood glucose and help 
explain hyper and hypoglycemia. 
The independent t-test was used for variables with continuous data, and the Mann Whitney U test was 
used for variables with categorical data. The age of the sample did not differ significantly: sliding-scale 
group (SS) age mean = 65.2 ± standard deviation = 9.6; basal-bolus group (BB) age 63.3 ± 11.8. Ethnicity 
of the sample revealed largely an African American population for both groups because of the hospital 
location, with smaller populations of white and Hispanic patients. 
The sex of the sample did not differ on the large number of women vs men. The admission glucoses 
were similar (SS 210.3 ± 149.5; BB 210.3 ± 138.2), and hemoglobin A1c values did not differ as both 
groups were admitted in fairly poor control (SS 8.3 ± 1.6; BB 8.2 ± 2.03). The white cell count did not 
reveal a large mean for infections being a major reason for admissions (SS 8.5 ± 3.3; BB 9.2 ± 4.2), and 
hemoglobin values did not indicate that anemia was significantly low, leading to an inaccurate 
Hemoglobin A1c value (SS 10.9 ± 2.3; BB 11.5 ± 2.8). 
Finally, though the creatinine value of the groups did not show a statistically significant difference (P = 
.395), the means indicated that a large portion of the SS group had high creatinines as compared to 
the BB group (SS 2.9 ± 3.3; BB 1.7 ± 1.6). This may be an interesting future study as another reason for 
the safety of using a BB regimen (Table 1). 
Table 1. Description of Sample/Demographic Variables 
Variable Sliding Scale Protocol 
Mean & SD (n = 64) 
Basal Bolus Protocol 
Mean & SD (n = 64) 
P value: Ind. t- 
test/MannWhitney U 
Age (years) 65.2 ± 9.6 63.3 ± 11.8 .273 
Ethnicity 59 AA, 2 W, 3 H 53 AA, 6 W, 5 H .244 
Sex 
(female/male) 
40 F, 24 M 38 F, 26 M .333 
Admission 
glucose 
210.3 ± 149.5 210.3 ± 138.2 .774 
Hemoglobin A1C 
(%) 
8.3 ± 1.6 8.2 ± 2.03 .860 
White blood cell 
count 
8.5 ± 3.3 9.2 ± 4.2 .190 
Hemoglobin 10.9 ± 2.3 11.5 ± 2.8 .526 
Creatinine 2.9 ± 3.3 1.7 ± 1.6 .395 
AA = African American; W = white; H = Hispanic. 
P = < 0.05. 
Statistical Analysis 
Statistical analysis was performed using the SPSS software package (IBM Corporation, Armonk, NY).7 
Independent t-tests were used to analyze continuous variables. Distributions on scores of several 
dependent variables were not normally distributed, and thus equality of variances was not assumed. 
Because of the possibility of a 30% type 1 error with multiple t tests, the confidence interval was set at 
70%. 
Results 
The means and standard deviations for variables associated with the hypotheses are reported in 
Table 2 where the P value demonstrated those variables that showed significance. The first hypothesis 
(H1) was that there would be a significant difference between BB and SSI protocols on fasting blood 
glucose, mean blood glucose, and discharge blood glucose. This hypothesis was supported with fasting 
blood glucose values: SS 201.4 ± 33.7; BB 135.5 ± 29.9, mean blood glucose values: SS 225 ± 37.5; BB 
149 ± 23.1, and discharge blood glucose values: SS 244.3 ± 68.2; BB 128.6 ± 27.3 (Table 2). 
Table 2. Results 
Variables Sliding 
Scale 
Protocol 
Mean & SD 
(n = 64) 
Basal Bolus 
Protocol 
Mean & SD 
(n = 64) 
Sig. (2-
tailed) 
t Std. Error 
Difference 
70% 
Confidence 
Interval 
 
      
Lower Upper 
Fasting 
blood 
glucose 
201.4 ± 
33.7 
135.5 ± 
29.9 
.000 11.711 5.62633 60.03521 71.74604 
Mean 
blood 
glucose 
225 ± 37.5 149 ± 23.1 .000 13.813 5.50101 70.25461 81.71414 
Discharge 
blood 
glucose 
244.3 ± 
68.2 
128.6 ± 
27.3 
.000 12.610 9.17937 106.17619 125.32381 
Mild/mod. 
hypo 
.6250 ± 
1.29 
.7031 ± 1.3 .730 −.345 .22623 −.31357 .15732 
Severe 
hypo 
.1719 ± .46 .1406 ± .59 .737 .336 .09296 −.06550 .12800 
Length of 
stay (days) 
4.6 ± 1.9 4.8 ± 2.8 .195 −.473 .42950 −.65012 .24387 
 
The second hypothesis (H2) was that there would be a significant difference in length of stay for BB 
and SSI protocols. This hypothesis was not supported as values included: SS 4.6 ± 1.9; BB 4.8 ± 2.8 
(Table 2). 
The third hypothesis (H3) was that there would be a significant difference in the incidence of 
mild/moderate and severe hypoglycemic episodes for BB and SSI protocols. This hypothesis was not 
supported with values for mild/moderate hypoglycemia (SS .6250 ± 1.29; BB .7031 ± 1.3) and for 
severe hypoglycemic episodes (SS .1719 ±.46; BB .1406 ±.59) (Table 2). 
Discussion 
Overall, this study was consistent with other research on BB regimens as far as improvements seen in 
fasting blood glucose, mean blood glucose, and discharge blood glucose.2, 5, 8, 9, 10, 13, 14 The results for 
H1 are consistent with Freedman et al5, in which patients on SSI had a mean blood glucose > 270 mg/dl 
(15.0 mmol/l). The mean blood glucose in this study for patients on the SSI protocol was 224 mg/dl 
(12.4 mmol/l). In Umpierrez et al11, the mean for SSprotocol patients was 193 mg/dl (10.7 mmol/l), and 
the mean fasting blood glucose was 165 mg/dl (9.17 mmol/l). The fasting blood glucose in this study 
for SS protocol patients was 201 mg/dl (11.17 mmol/l). These results are all higher than the pre-meal 
glucose target of < 140 mg/dl (7.78 mmol/l) and random glucose target of < 180 mg/dl (10.0 mmol/l) as 
set by the American Diabetes Association, suggesting that SSI protocols do not meet the standards for 
achieving good glycemic control in this study.3 
The analysis of hypoglycemia revealed that there were no statistically significant results regarding 
episodes of mild/moderate (< 70 mg/dl or 3.9 mmol/l) or severe hypoglycemia (< 50 mg/dl or 2.8 
mmol/l). There were a slightly larger number of episodes of mild/moderate hypoglycemia with BB 
therapy than with SS therapy and slightly more episodes of severe hypoglycemia with SS therapy as 
compared to BB therapy. This is consistent with other studies as far as SS being a potentially dangerous 
therapy as compared to BB therapy.5, 10, 15 
The analysis of the LOS data was also not statistically significant between BB and SS groups. The mean 
LOS were similar for both groups, and compared to Umpierrez et al11, this study actually had shorter 
LOS. 
The analysis of the other variables concluded that there were no statistically significant differences in 
age, ethnicity, sex, white blood cell count, hemoglobin, creatinine, A1C, or admission blood glucose for 
either group. 
The knowledge and expertise in diabetes of the advanced practice nurse, along with a specialty 
flowsheet within the electronic medical record, provided consistency and reliability in how the data 
were collected. Finally, the sample consisted of patients from medical units with a prior diagnosis of 
type 2 diabetes, so this was a fairly homogeneous convenience sample from 1 hospital. 
Limitations 
One limitation of this study included its retrospective design. The retrospective electronic medical 
record does not allow the researcher to inquire why decisions were made. For example, glucose 
readings may have been taken shortly after the patient had begun eating and the insulin dose may not 
have been timed appropriately with meals. This hospital allowed “on-demand meals,” and thus 
patients could order meals when they wanted and would receive and start eating the meal without the 
staff RN's knowledge. The meal-time insulin would then be given late. Since this study was done, a 
system was put into place whereby a sign on the door alerted the kitchen staff to contact the patient's 
RN before giving the patient a tray. 
Generalizability of the results was limited because of the sample being from noncritical care units and 
because the sample was obtained from a single central-city hospital. Thus, though the study is 
replicable, it may not be representative of diabetes care in other settings. 
Another limitation of this study is that it did not track how many patients were admitted because they 
had infections compared to how many were admitted only for poorly controlled diabetes. 
Conclusion 
The results of this project provide direction for improving the care of hospitalized patients with 
hyperglycemia in this facility. The evidence that BB insulin protocols provide improved glycemic control 
over SS protocols in this facility needs to be presented to all caregivers. 
NPs specializing in diabetes are key members of the inpatient care team for the translation of research 
related to evidence-based diabetes practice. In addition to providing this evidence, NPs specializing 
in diabetes should be included on committees that write institutional guidelines on when and how to 
initiate and change/adjust insulin therapy. This topic should be part of every orientation for 1st year 
residents and part of the yearly competency skills for RNs. 
Protocols via the electronic medical record should also be designed to allow staff nurses to implement 
interventions independently such as basal/bolus dos-ing based on a patient's weight. Inpatient 
diabetes update sessions would also benefit other prescribers such as hospitalists and external 
providers who still admit their own patients. The advanced practice diabetes educator can be 
instrumental in coordinating future studies to assess progress with the use evidence-based practice 
diabetes protocols, as well as studies that assess the rate of 30-day readmissions for uncontrolled 
hyperglycemia since this is now being scrutinized regarding reimbursement.12 
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